Navigation Links
HRT Found To Increase Recurrence of Breast Cancer

A new study assessing the use of hormone replacement therapy among breast cancer survivors has been // stopped early because results indicate an unacceptably high rate of recurring or new cancers.

Swedish researchers embarked on the study in part because more women are surviving the disease and therefore subject to the same menopausal symptoms as other women. The study was expected to involve around 1,300 women over five years. After the initial 345 women in the study were followed for about two years, however, results showed 26 of those randomized to receive HRT experienced a new or recurring cancer, compared to just seven in a placebo group. The risk was deemed unacceptable, and the study was halted on December 17, 2003.

Noting some doctors prescribe HRT for their breast cancer patients with severe menopausal symptoms because observational studies have suggested no harm from the treatment, specialists say , “This study will no doubt change that. It is large enough and clear enough to show that HRT appears to increase the chance of a new or recurring breast cancer. Because of that, offering HRT to women with a history of breast cancer would be unwise.”

Researchers conclude saying , alternative safe and effective strategies for the difficult problem of menopausal symptoms in these women now need to be developed.
'"/>




Page: 1

Related medicine news :

1. Fluoride Found Effective in Osteoporosis
2. Implantable Contact Lens Found Safe and Effective
3. Cancer hazard Found With Animal-Based Nutrients
4. Processed Meat, Diabetes connection Found
5. Night Time Aspirin Regimen Found to Reduce Blood Pressure
6. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
7. Hydrotherapy Found to be Effective for Patients with Osteoarthritis
8. Preventive Therapies Found to be More Effective in Managing Migraines
9. Common Cold Found to Fight Cancer
10. Circumcision Found To Prevent HIV Spread
11. Drug Found To Reduce The Transmission Of Herpes
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... Compliance and Safety for the President’s Malaria Initiative (PMI) Africa Indoor Residual ... Innovation to Action Award. , The Innovation to Action Award, a USAID ...
(Date:9/19/2017)... ... 2017 , ... MelaKids, a Laredo-based company, has introduced a new concept for ... Nature gives us a full supply of melanin – in the back of the ... glare-reducing pigment; however, around the age of thirty, we develop a yellow-brown pigment in ...
(Date:9/19/2017)... ... 19, 2017 , ... The Workgroup for Electronic Data Interchange (WEDI) , ... in healthcare information exchange and a trusted advisor to the U.S. Department of Health ... entitled Barriers to Adoption of the ERA and EFT Transactions . , ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the ... industry itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. ... natural alkaline water technologies, water filtration systems, and consumer education. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... TX, announces the launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone ... the first in the U.S. to incorporate magnesium, a critical property for bone ...
Breaking Medicine News(10 mins):
(Date:9/13/2017)... OrthoAtlanta has been named the official orthopedic and sports ... the 2018 College Football Playoff (CFP) National Championship to be ... Atlanta, Georgia . OrthoAtlanta is proud to ... in many activities leading up to, and including the national ... OrthoAtlanta ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
Breaking Medicine Technology: